These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17699445)

  • 1. Through the looking glass: anemia guidelines, vested interests, and distortions.
    Ingelfinger JR
    Clin J Am Soc Nephrol; 2007 May; 2(3):415-7. PubMed ID: 17699445
    [No Abstract]   [Full Text] [Related]  

  • 2. [Transfusion requirements in chronic kidney disease].
    Frimat L
    Transfus Clin Biol; 2008 Nov; 15(5):214-6. PubMed ID: 18938100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE; Szczech LA
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conflict of interest in clinical guidelines should be avoided.
    Shaldon S
    Nephrol Dial Transplant; 2008 May; 23(5):1771; author reply 1772. PubMed ID: 18187498
    [No Abstract]   [Full Text] [Related]  

  • 5. Adverse consequences with use of erythropoiesis-stimulating agents in anemia prompt release of guidelines to ensure safe use and maximize benefit.
    Dharmarajan TS; Widjaja D
    Geriatrics; 2008 Jun; 63(6):13-29. PubMed ID: 18512996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients - an eye-opener.
    Binnani PG
    Saudi J Kidney Dis Transpl; 2009 Nov; 20(6):1090. PubMed ID: 19861881
    [No Abstract]   [Full Text] [Related]  

  • 7. Separating practice guidelines from pharmaceutical marketing.
    Eichacker PQ; Natanson C; Danner RL
    Crit Care Med; 2007 Dec; 35(12):2877-8; author reply 2878-80. PubMed ID: 18043217
    [No Abstract]   [Full Text] [Related]  

  • 8. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
    Walker RG
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
    [No Abstract]   [Full Text] [Related]  

  • 9. Conflicts of interest and viewpoint bias in KDOQI and KDIGO workgroups.
    Coyne DW
    Nephrol Dial Transplant; 2008 Dec; 23(12):4071; author reply 4071-2. PubMed ID: 18768584
    [No Abstract]   [Full Text] [Related]  

  • 10. Commentary on "Influence of industry on renal guideline development".
    Campbell D; Walker R; Mathew T; Craig J
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):211. PubMed ID: 17699413
    [No Abstract]   [Full Text] [Related]  

  • 11. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N
    Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease.
    Vaziri ND; Zhou XJ
    Nephrol Dial Transplant; 2009 Apr; 24(4):1082-8. PubMed ID: 18987263
    [No Abstract]   [Full Text] [Related]  

  • 13. Is industry guiding the sepsis guidelines? A perspective.
    Durbin CG
    Crit Care Med; 2007 Mar; 35(3):689-91. PubMed ID: 17255867
    [No Abstract]   [Full Text] [Related]  

  • 14. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target.
    KDOQI
    Am J Kidney Dis; 2007 Sep; 50(3):471-530. PubMed ID: 17720528
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of testosterone in bilateral nephrectomized dialysis patients.
    Shaldon S; Patyna WD; Kaltwasser P; Werner E; Koch KM; Schoeppe WE
    Trans Am Soc Artif Intern Organs; 1971; 17():104-7. PubMed ID: 5158074
    [No Abstract]   [Full Text] [Related]  

  • 16. [Erythropoiesis-stimulating agents in chronic kidney disease: which route of administration?].
    Borrelli S; Baldanza D; Scigliano R; Catapano F; Grimaldi M; Calabria M; Zamboli P; Minutolo R; De Nicola L; Conte G
    G Ital Nefrol; 2009; 26(1):31-7. PubMed ID: 19255962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vested interests--you and us.
    Jackson G
    Int J Clin Pract; 2000 Sep; 54(7):414. PubMed ID: 11070560
    [No Abstract]   [Full Text] [Related]  

  • 18. Influence of industry on renal guideline development.
    Coyne DW
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):3-7; discussion 13-4. PubMed ID: 17699377
    [No Abstract]   [Full Text] [Related]  

  • 19. Anemia of chronic kidney disease: CHOIR and the FDA.
    Singh AK
    Nat Clin Pract Nephrol; 2007 Aug; 3(8):406-7. PubMed ID: 17593919
    [No Abstract]   [Full Text] [Related]  

  • 20. Strategies for successfully managing the anemia of chronic kidney disease in the long-term care setting.
    Germain MJ
    Consult Pharm; 2008 Mar; 23 Suppl A():11-7. PubMed ID: 18454575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.